The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2021
Filed:
Feb. 21, 2019
Applicants:
Bristol-myers Squibb Company, Princeton, NJ (US);
Roche Innovation Center Copenhagen A/s, Hørsholm, DK;
Inventors:
Richard E. Olson, Cambridge, MA (US);
Brian R. Anderson, Princeton, NJ (US);
Peter Hagedorn, Hørsholm, DK;
Marianne Lerbech Jensen, Køge, DK;
Ivar M. McDonald, East Haddam, CT (US);
Stephen E. Mercer, Middletown, CT (US);
Assignees:
BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);
ROCHE INNOVATION CENTER COPENHAGEN A/S, Horsholm, DK;
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61K 47/60 (2017.01); A61P 9/12 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39541 (2013.01); A61K 9/0017 (2013.01); A61K 9/0019 (2013.01); A61K 31/713 (2013.01); A61K 47/542 (2017.08); A61K 47/549 (2017.08); A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61P 9/04 (2018.01); A61P 9/12 (2018.01); C12N 5/0607 (2013.01); C12N 5/0657 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); A61K 2039/505 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3525 (2013.01); C12N 2320/30 (2013.01); C12Y 207/11017 (2013.01);
Abstract
The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.